SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Stellar is an open-source, decentralized network co-founded in 2014 by Jed McCaleb and Joyce Kim to facilitate the fast and low-cost transfer of value across different currencies and assets globally. Managed by the non-profit Stellar Development Foundation, the project serves as a global infrastructure that connects banks, payment systems, and individuals to expand financial access to underserved populations. Its main value proposition lies in providing a bridge between traditional money and digital networks through the use of Anchors, which are trusted entities that hold deposits and issue credits on the ledger.  The network operates using the Stellar Consensus Protocol and a Federated Byzantine Agreement, where nodes choose trusted sets of other nodes to agree on the state of the ledger. This system ensures high throughput and fast finality, where transactions are considered permanent and irreversible within seconds. Key features include a built-in distributed exchange for trading assets without intermediaries and the Soroban platform for developing smart contracts. Users can also utilize the network for tokenizing real-world assets or accessing decentralized finance services like peer-to-peer lending.  Stellar's native token, XLM, is essential for maintaining network integrity by acting as an intermediary to find efficient exchange paths and preventing spam through small transaction fees and minimum account balance requirements. Unlike many other digital assets, the network has no inflation because the community voted to disable the automatic creation of new tokens. While the project received early funding from the payments company Stripe, it is now sustained by a global community of validators and developers rather than traditional venture capital.

Stellar Lumens

Stellar Lumens is trending due to a major partnership with the DTCC, a financial giant that processes trillions of dollars in securities transactions, to bring tokenized stocks and treasuries onto the Stellar blockchain. The community is actively discussing the potential for institutional-grade utility and a massive short squeeze, with many comparing its long-term growth prospects to other prominent payment-focused assets.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is experiencing significant volatility and community debate as investors navigate recent token unlocks and airdrop distribution schedules. While bulls are focused on the project's privacy-focused ZK-proof technology and its integration within the Cardano ecosystem, skeptics are actively discussing concerns regarding market cap valuations and the long-term impact of circulating supply.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending as the community doubles down on its 'permissionless brand' model, actively showcasing diverse real-world products like energy drinks, apparel, and spices to differentiate itself from traditional meme coins. Supporters are consistently highlighting the project's organic growth, strong grassroots conviction, and ongoing IRL initiatives as proof of long-term utility and brand potential.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is currently seeing a surge in community discussion as investors debate its potential for a major price breakout while weighing its long-term viability against broader crypto market trends and competing meme coin narratives. Sentiment remains highly polarized, with many users focused on technical support levels and historical chart patterns while others express frustration over stagnant performance compared to other asset classes.

Billions is the global human and AI network, built on mobile-first verification to scale the internet of value. We uniquely verify the identity and uniqueness of humans and AI agents, empowering users with personalized experiences and rewards.  ‍Our network is designed to be accessible, scalable, and anonymous, making trust between humans and AI seamless and intuitive for everyone.

TillBilly

BILL is experiencing high volatility as investors track thin liquidity and supply-side activity, fueling intense debate between traders anticipating a short squeeze and skeptics warning of manipulation. Community sentiment remains sharply divided over whether the token is poised for a significant breakout or mirrors past cycles of pump-and-dump patterns.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is currently trending as investors focus on the upcoming PDUFA date for its lung cancer candidate ivonescimab, while the community debates the significance of Phase 3 trial data and the potential competitive threat to existing immunotherapy standards. Discussions are dominated by speculation regarding institutional accumulation, the impact of recent analyst downgrades, and strong conviction from long-term holders anticipating that clinical results will ultimately validate the stock's valuation.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is currently seeing a surge in investor interest and market activity driven by the integration of traditional financial assets like S&P 500 futures on its platform, positioning it as a significant hub for 24/7 decentralized trading. The community is actively discussing its potential for institutional adoption and price discovery, with many comparing its long-term potential to foundational infrastructure within the broader perpetual derivatives market.

Flutter Entertainment Plc engages in the business of online betting and gaming. It operates through the following segments: UK and Ireland, Australia, International, and US. The UK and Ireland segment includes the operations of Sky Betting and Gaming, Paddy Power, Betfair, and tombola. The Australia segment focuses on sports betting services provided to Australian customers online. The International segment relates to poker, casino, rummy, lottery, and sports betting. The US segment includes sports betting, daily fantasy sports, and gaming services. The company was founded in 1988 and is headquartered in New York, NY.

Flutter Entertainment Plc

Flutter Entertainment is experiencing heightened investor attention following a significant management reshuffle and ongoing volatility linked to increased regulatory scrutiny surrounding prediction markets. While the community actively debates whether the stock's current valuation offers a deep-value opportunity or if intensifying competition from emerging betting platforms will continue to pressure long-term growth, investors are closely monitoring potential legislative responses to these new wagering products.

Direxion Shares ETF Trust - Direxion Daily S&P 500 High Beta Bull 3X ETF

Direxion Daily S&P 500 High Beta Bull 3X Shares

Traders are actively using HIBL as a leveraged instrument to capitalize on S&P 500 swings, often rotating between the bull and bear variants in response to market volatility. The community continues to debate the impact of decay and leverage in these high-beta ETFs while monitoring broader trend signals.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

Mineralys Therapeutics is trending as investors digest new clinical data for lorundrostat presented at a major hypertension conference, while the community actively debates the stock's potential for a buyout or strategic partnership ahead of upcoming regulatory milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum

Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum PR Newswire NEW YORK, May 28, 2026 USA News Group News CommentaryIssued on behalf ofAva Bio, Inc.As...

If You Invested $100 In Alnylam Pharmaceuticals Stock 10 Years Ago, You Would Have This Much Today

Alnylam Issues 2025 Corporate Responsibility Report

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the publication of its 2025 Corporate Responsibility Report. The 2025 report details how the company is scaling its corporate responsibility efforts in tandem with its business growth. Reflected...

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of...

Alnylam to Webcast Presentations at Upcoming Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: BofA Securities Healthcare Conference on Wednesday, May 13, 2026, at 10:40 am PT (1:40 pm ET) in Las...

Bronte Capital Management Pty Ltd. Has $15.45 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Bronte Capital Management Pty Ltd. boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11.1% in the 4th quarter, according to the company in its most recent filing...

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type...

PFA Pension Forsikringsaktieselskab Buys Shares of 35,405 Alnylam Pharmaceuticals, Inc. $ALNY

PFA Pension Forsikringsaktieselskab bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 35,405 shares of the biopharmaceutical company's stock, v...

PKO Investment Management Joint Stock Co Increases Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

PKO Investment Management Joint Stock Co boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 750.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,800 shares of the biopharmaceutical company's stock afte...

Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 53.1% during the fourth quarter, according to its most recent Form...

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

ALNY
Alnylam Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest ALNY News

ALNYAlnylam Pharmaceuticals Inc